NCT02047747View on ClinicalTrials.gov

A Phase II Study of Dacomitinib in Progressive Brain Metastases

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Brain Cancer
Interventions
DRUG

Dacomitinib

Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.

Trial Locations (1)

92093-0698

UCSD Moores Cancer Center, La Jolla

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

David Piccioni, M.D., Ph.D

OTHER

NCT02047747 - A Phase II Study of Dacomitinib in Progressive Brain Metastases | Biotech Hunter | Biotech Hunter